SOPH Stock Forecast & Price Target

Sophia Genetics is poised for continued growth with a strong track record of increasing revenue and a focus on maximizing revenue from existing customers. This is supported by their successful applications in heme, solid tumor, and rare disease, as well as a multi-year extension with AstraZeneca. Additionally, their plans to offer new applications and their competitive advantage in their patient database and biopharma business make them a strong player in the healthcare technology market. With a positive outlook and a buy rating from analysts, SOPH is expected to continue to raise funds and potentially reach profitability in the future.

Sophia Genetics is facing challenges in converting new customers and recognizing revenue, as many health systems are still in the "conversion process" and revenues may not be recognized until the second half of 2026. Additionally, despite its expansion and partnerships with prestigious institutions such as Mayo Clinic and Mt. Sinai, Sophia Genetics is not expected to reach Adj. EBITDA breakeven until 2026 and may continue to incur losses in the future. There are also concerns about potential competition from companies like Tempus, which also offers data-driven medicine solutions and has incurred significant losses.